(Reuters) – The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc’s drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.
The U.S. drugmaker’s shares fell 10.4 percent to $87.90 in afternoon trading following the news.
